Evaluation of Quality of Life on Functional, Symptoms, and Global Health Status in Breast Cancer Patients among Chemotherapy Cycles with Cyclophosphamide-Doxorubicin-5Fluorouracil

Indonesian Journal of Clinical Pharmacy Pub Date : 2021-12-30 DOI:10.15416/ijcp.2021.10.4.261

S. Saleha, A. Vonna, Sarah Firdausa

{"title":"Evaluation of Quality of Life on Functional, Symptoms, and Global Health Status in Breast Cancer Patients among Chemotherapy Cycles with Cyclophosphamide-Doxorubicin-5Fluorouracil","authors":"S. Saleha, A. Vonna, Sarah Firdausa","doi":"10.15416/ijcp.2021.10.4.261","DOIUrl":null,"url":null,"abstract":"Treatment of breast cancer with chemotherapy in several cycles has led to differences in patients' quality of life. One of the chemotherapy recommendations for breast cancer is Cyclophosphamide-Doxorubicin-5Fluorouracil (CAF). Therefore, this research aimed to determine the quality of life among chemotherapy cycles with CAF in breast cancer patients at Dr. Zainoel Abidin Hospital Banda Aceh. This is an observational analytic study with the cross-sectional method, where 32 patients were obtained through a total sampling technique from June to August 2019. Quality of life was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30), while the Kruskal-Wallis test performed the statistical analysis. The results showed that the quality of life of breast cancer patients has no significant difference among chemotherapy cycles with CAF (p>0,05). However, some changes in the functional and symptom scale among patients required a further follow-up by healthcare professionals to improve the quality of life.","PeriodicalId":351729,"journal":{"name":"Indonesian Journal of Clinical Pharmacy","volume":"59 10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indonesian Journal of Clinical Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15416/ijcp.2021.10.4.261","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Treatment of breast cancer with chemotherapy in several cycles has led to differences in patients' quality of life. One of the chemotherapy recommendations for breast cancer is Cyclophosphamide-Doxorubicin-5Fluorouracil (CAF). Therefore, this research aimed to determine the quality of life among chemotherapy cycles with CAF in breast cancer patients at Dr. Zainoel Abidin Hospital Banda Aceh. This is an observational analytic study with the cross-sectional method, where 32 patients were obtained through a total sampling technique from June to August 2019. Quality of life was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30), while the Kruskal-Wallis test performed the statistical analysis. The results showed that the quality of life of breast cancer patients has no significant difference among chemotherapy cycles with CAF (p>0,05). However, some changes in the functional and symptom scale among patients required a further follow-up by healthcare professionals to improve the quality of life.

查看原文本刊更多论文

环磷酰胺-阿霉素-5氟尿嘧啶化疗周期中乳腺癌患者的功能、症状和整体健康状况的生活质量评价

在几个周期的化疗中治疗乳腺癌导致了患者生活质量的差异。乳腺癌的化疗建议之一是环磷酰胺-阿霉素-5氟尿嘧啶(CAF)。因此，本研究旨在确定在班达亚齐Zainoel Abidin医生医院接受CAF化疗周期的乳腺癌患者的生活质量。这是一项采用横断面法的观察性分析研究，于2019年6月至8月通过全抽样技术获得32例患者。生活质量采用欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ C-30)进行测量，采用Kruskal-Wallis检验进行统计分析。结果显示，不同化疗周期CAF对乳腺癌患者的生活质量无显著影响(p> 0.05)。然而，患者在功能和症状量表上的一些变化需要医疗保健专业人员进一步随访以改善生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indonesian Journal of Clinical Pharmacy

自引率

0.00%

发文量